Drug Profile
Emtricitabine/rilpivirine/tenofovir alafenamide - Gilead Sciences/ Janssen
Alternative Names: FTC/RPV/TAF; Odefsey; R/F/TAF; Rilpivirine/emtricitabine/tenofovir alafenamide; Tenofovir alafenamide/rilpivirine/emtricitabineLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Gilead Sciences; Janssen
- Class Antiretrovirals; Benzonitrile; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Pyrimidines; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 01 May 2021 Registered for HIV-1 infections (In children, In adolescents, In adults) in Switzerland, prior to May 2021 (PO)
- 31 Dec 2020 Gilead Sciences has patent protection for emtricitabine/rilpivirine/tenofovir alafenamide in USA and European Union
- 09 Jan 2019 Gilead completes a phase IIIb trial in HIV-1 infections (Treatment experienced) in USA, Belgium, Canada, France, Germany, Italy, Netherlands, Puerto Rico, Spain, Sweden, Switzerland, United Kingdom (NCT02345252)